A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trial

Official title:

An Open Label Trial of BI 765063 in Combination With BI 754091 (Ezabenlimab) Alone or With BI 836880, Chemotherapy, or Cetuximab, in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) or Hepatocellular Carcinoma (HCC)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05249426
• Other study ID #: 1443-0002
• Secondary ID: 2021-003473-59
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: February 25, 2022
• Est. completion date: August 2, 2025

Study information

• Verified date: May 2024
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is open to adults with head and neck cancer or liver cancer. This is a study for people for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out whether combining different medicines make tumours shrink in people with head and neck cancer or liver cancer. The tested medicines in this study are antibodies that act in different ways against cancer. BI 765063 and ezabenlimab may help the immune system fight cancer (checkpoint inhibitors). Cetuximab blocks growth signals and may prevent the tumour from growing. BI 836880 blocks the formation of new blood vessels that the tumour needs to grow. All participants get BI 765063 and ezabenlimab. One group gets no additional medicine. The other groups get either BI 836880, cetuximab, or chemotherapy. BI 765063, ezabenlimab, and BI 836880 are given as infusions into veins every 3 weeks. Cetuximab is given as an infusion every 1 or 2 weeks. Participants can stay in the study as long as they benefit from treatment and can tolerate it. The doctors monitor the size of the tumour. The doctors also regularly check participants' health and take note of any unwanted effects.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 48
• Est. completion date: August 2, 2025
• Est. primary completion date: November 29, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed informed consent form (ICF) prior to any trial-specific procedures.
• Male or female aged = 18 years at the time of ICF signature.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at the screening visit.
• Expected life expectancy of at least 3 months.
• Patients homozygous for V1 allele (including V1-like alleles) of Singal Regulatory Protein-alpha (SIRPa) (V1/V1 SIRPa genotype). SIRPa polymorphism will be assessed in blood sampling (using patient Deoxyribonucleic Acid [DNA]) during Screening 1 Visit.
• Patients with at least one measurable lesion as per Response Evaluation Critiera In Solid Tumours (RECIST) version 1.1 (v1.1).
• Patients must agree to provide a mandatory pre-treatment (baseline) biopsy and an ontreatment fresh tumour biopsy (unless medically contraindicated. or mandatory requirement is lifted by the sponsor). Details on biopsy sample collection are provided in the Lab Manual. -- Pre-treatment (baseline) biopsy: A fresh tumour biopsy before receiving the trial medication is preferred. In case a fresh tumour biopsy cannot be obtained, the Sponsor must be notified and archival formalin-fixed paraffin embedded (FFPE) tumour tissue block from the most recent time point before entering the trial must be provided (maximum 6 months prior to study entry). If these requirements cannot be met, the patient may still be allowed to enter the study at the discretion of the sponsor, after discussion between the Investigator and Sponsor.
• Female patients. Women of childbearing potential (WOCBP) must agree to use highly effective methods of contraception per ICH M3 (R2), that results in a less than 1% per year failure rate when used consistently and correctly, starting at the screening visit, during the trial and for 6 months after the end of trial treatment. The requirement of contraception does not apply to women of no childbearing potential, but they must have evidence of such at screening. Women of childbearing potential must have a serum negative pregnancy test within 72 hours prior to first drug administration. Women who are postmenopausal for at least 1 year (defined as more than 12 months since last menses) or are surgically sterilized do not require this test. The following methods of

contraception are considered highly effective:

• Combined (oestrogen and progestogen containing) hormonal birth control that prevents ovulation (oral, intravaginal, transdermal)
• Progestogen-only hormonal birth control that prevents ovulation (oral, injectable, implantable)
• Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)
• Bilateral tubal occlusion
• Vasectomised partner (provided that this is the sole sexual partner and has received medical assessment of the surgical success)
• Sexual abstinence (if accepted by local ethics boards and regulatory agencies as highly effective) Sexual abstinence is defined as refraining from heterosexual intercourse during the entire study period from screening through 6 months after last trial treatment. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception for use during this trial. Although use of a contraceptive pill and Intrauterine device (IUD) together are considered a highly- effective method of birth control, women of childbearing potential taking a contraceptive pill must use an additional barrier method for the entire duration of the trial treatment intake and for 6 months after the end of the trial treatment intake. WOCBP is defined as: fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Tubal ligation is NOT a method of permanent sterilisation. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. Further inclusion criteria apply.

Exclusion criteria:

• Patients with at least one SIRPa V2 allele, i.e. SIRPa V1/V2 or V2/V2 individuals.
• Patients with symptomatic/active central nervous system (CNS) metastases. Patients with previously treated brain metastases are eligible, if there is no evidence of progression for at least 28 days before the first trial drug administration without requirement for treatment with corticosteroids, as ascertained by clinical examination and brain imaging (MRI (magnetic resonance imaging) or CT (computed tomography)) during the screening period.
• Prior allogeneic stem cell or solid organ transplantation.
• Any tumour location necessitating an urgent therapeutic intervention (e.g., palliative care, surgery or radiation therapy, such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture).
• Presence of active invasive cancers other than the one treated in this trial within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin, or in situ carcinoma of uterine cervix, or other local tumours considered cured by local treatment.
• Patients with active autoimmune disease or a documented history of autoimmune disease, that requires systemic treatment, i.e. corticosteroids or immunosuppressive drugs, except patients with vitiligo, resolved childhood asthma/atopy, alopecia, or any chronic skin condition that does not require systemic therapy; patients with autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and/or controlled Type 1 diabetes mellitus on a stable insulin regimen are eligible.
• History of severe hemorrhagic or thromboembolic event in the past 12 months (excluding central venous catheter thrombosis, peripheral deep vein thrombosis and portal vein thrombosis due to HCC tumor invasion).
• Known prior history of severe infusion related reactions to monoclonal antibodies (Grade = 3 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events (CTCAE) v5.0). Further exclusion criteria apply.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Head and Neck Squamous Cell Carcinoma (HNSCC)
• Squamous Cell Carcinoma of Head and Neck

Intervention

Drug:
• BI 765063
BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPa) Monoclonal Antibody (mAb))
• Ezabenlimab
Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))
• BI 836880
BI 836880 (anti-Vascular Endothelial Growth Factor (VEGF) / Angiopoetin 2 (Ang2))
• Cetuximab
Cetuximab

Other:
• Investigator´s Choice Chemotherapy
Allowable chemotherapies include: paclitaxel, docetaxel, capecitabine, 5-fluorouracil, methotrexate or combinations thereof

Locations

Country	Name	City	State
France	CTR Georges-François Leclerc	Dijon
France	CTR Leon Berard	Lyon
France	HOP Timone	Marseille
France	INS Curie	Paris
France	HOP Civil	Strasbourg
France	INS Claudius Regaud IUCT-Oncopole	Toulouse
Japan	Japanese Foundation for Cancer Research	Tokyo, Koto-ku
Malaysia	Hospital Sultan Ismail	Johor Bahru
Malaysia	University of Malaya Medical Centre	Kuala Lumpur
Malaysia	Sarawak General Hospital	Kuching, Sarawak
Malaysia	National Cancer Institute (IKN)	Putrajaya
Mexico	ARKE SMO S.A. de C.V	Ciudad de Mexico
Mexico	Hospital Universitario Dr Jose Eleuterio Gonzalez	Monterrey
Mexico	FAICIC S de RL de C.V.	Veracruz
Mexico	Investigacion Biomedica para el Desarrollo de Farmacos, S.A. de C.V.	Zapopan
Moldova, Republic of	ARENSIA Exploratory Medicine	Chisinau
Poland	Medical University Gdansk	Gdansk
Poland	Mandziuk Slawomir Specialist Medical Practice	Lublin
Romania	"Prof. Dr. Alexandru Trestioreanu" Oncology Institut	Bucharest
Romania	Institutul Oncologic "Prof. Dr. Ion Chiricuta"	Cluj-Napoca
Spain	Hospital Vall d'Hebron	Barcelona
Spain	Hospital Duran i Reynals	L'Hospitalet de Llobregat
Spain	Hospital Clínico San Carlos	Madrid
Thailand	King Chulalongkorn Memorial Hospital	Bangkok
Thailand	Ramathibodi Hospital	Bangkok
Thailand	Songklanagarind Hospital	Songkla
United Kingdom	Hammersmith Hospital	London
United Kingdom	King's College Hospital	London
United Kingdom	The Royal Marsden Hospital, Chelsea	London
United States	Valkyrie Clinical Trials	Los Angeles	California
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States,  France,  Japan,  Malaysia,  Mexico,  Moldova, Republic of,  Poland,  Romania,  Spain,  Thailand,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response (OR)	Objective response (OR) with confirmation, defined as the best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 (v1.1) by investigator's assessment from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, lost to follow-up or withdrawal of consent.	Up to 12 months.
Secondary	Occurrence of treatment emergent adverse events (AEs)	Occurrence of treatment emergent adverse events (AEs) by investigator's assessment from first treatment administration until the earliest of death, subsequent anti-cancer therapy, lost to follow-up or withdrawal of consent.	Up to 12 months.
Secondary	Duration of objective response (DOR)	Duration of objective response (DOR), defined as the time from first documented complete response (CR) or partial response (PR) (RECIST v1.1) until the earliest of progressive disease (PD) or death among patients with objective response (OR).	Up to 12 months.
Secondary	Disease control (DC)	Disease control (DC), defined as best overall response of complete reponse (CR), partial reponse (PR), or stable disease (SD) where best overall response is defined according to RECIST v1.1 as assessed by the Investigator until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, or permanent treatment discontinuation.	Up to 12 months.
Secondary	Progression-free survivial (PFS)	Progression-free survival (PFS), defined as the time from first treatment administration until progressive disease (PD) according to RECIST v1.1 or death from any cause, whichever occurs earlier.	Up to 12 months.

External Links

•   Related Info